NervGen Pharma Corp.
NGENF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $240 | $247 | $203 | $220 |
| - Cash | $11 | $16 | $14 | $17 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $229 | $231 | $189 | $203 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$6 | -$6 | -$6 | -$7 |
| % Margin | – | – | – | – |
| Net Income | -$4 | -$9 | -$4 | -$9 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.06 | -0.13 | -0.056 | -0.12 |
| % Growth | 53.8% | -132.6% | 53.4% | – |
| Operating Cash Flow | -$5 | -$4 | -$4 | -$4 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$5 | -$4 | -$4 | -$4 |